Media headlines about Medidata Solutions (NASDAQ:MDSO) have been trending somewhat positive this week, according to Accern. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Medidata Solutions earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.1141620093852 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
Shares of Medidata Solutions (MDSO) traded up $0.89 on Thursday, reaching $65.47. 292,829 shares of the company’s stock were exchanged, compared to its average volume of 545,414. The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.37 and a current ratio of 1.29. Medidata Solutions has a 1 year low of $47.77 and a 1 year high of $85.92. The company has a market capitalization of $3,799.38, a price-to-earnings ratio of 78.30, a P/E/G ratio of 4.05 and a beta of 1.69.
Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings results on Thursday, October 26th. The company reported $0.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. The firm had revenue of $140.08 million for the quarter, compared to analyst estimates of $141.27 million. During the same quarter in the previous year, the firm posted $0.28 earnings per share. The business’s revenue was up 16.7% on a year-over-year basis. research analysts forecast that Medidata Solutions will post 0.77 EPS for the current year.
A number of research analysts recently issued reports on the stock. KeyCorp restated a “buy” rating and set a $86.00 price objective on shares of Medidata Solutions in a report on Sunday, September 17th. Royal Bank Of Canada assumed coverage on shares of Medidata Solutions in a report on Tuesday, September 19th. They set a “sector perform” rating and a $82.00 price objective for the company. Zacks Investment Research upgraded shares of Medidata Solutions from a “sell” rating to a “hold” rating in a report on Wednesday, September 20th. SunTrust Banks restated a “buy” rating and set a $92.00 price objective on shares of Medidata Solutions in a report on Friday, October 27th. Finally, Wells Fargo & Company decreased their price objective on shares of Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating for the company in a report on Friday, October 27th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $85.08.
In other news, EVP Michael I. Otner sold 10,000 shares of the business’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $70.88, for a total value of $708,800.00. Following the sale, the executive vice president now owns 80,674 shares of the company’s stock, valued at $5,718,173.12. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Tarek Sherif sold 200,000 shares of the business’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $68.76, for a total transaction of $13,752,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 237,010 shares of company stock worth $16,305,136. Insiders own 5.80% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Medidata Solutions (MDSO) Stock Price” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/08/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-medidata-solutions-mdso-stock-price.html.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc and related companies with MarketBeat.com's FREE daily email newsletter.